#1 Rankings With a Side of Sass: Habit Burger Tops USA TODAY 10Best with Multiple Wins, Runner-Ups Get a Billboard Shoutout GlobeNewswire August 13, 2025 Habit dominates USA TODAY 10Best and makes sure the competition sees it IRVINE, Calif., Aug. 13, 2025 (GLOBE NEWSWIRE) — The grills at Habit Burger & Grill aren't the only […]
BrainsWay Reports Second Quarter 2025 Financial Results and Operational Highlights GlobeNewswire August 13, 2025 Achieved record quarterly revenue of $12.6 million in Q2 2025, an increase of 26% compared to Q2 2024 Operating profit totaled $0.6 million and Adjusted EBITDA rose to $1.5 million, Raised full-year 2025 Revenue and EBITDA guidance Remaining performance obligations increased
Personal Protective Equipment Market worth $77.66 billion by 2030, at a CAGR of 5.49%, says MarketsandMarkets(TM) GlobeNewswire August 13, 2025 Delray Beach, FL, Aug. 13, 2025 (GLOBE NEWSWIRE) — The Global Personal Protective Equipment Market was valued at USD 56.64 billion in 2024 and is projected to reach USD 77.66 billion by 2030, growing at
PolyPid Provides Corporate Update and Reports Second Quarter 2025 Financial Results GlobeNewswire August 13, 2025 Positive Phase 3 SHIELD II Trial Results – D-PLEXâ‚₀₀ successfully met its primary efficacy endpoint and demonstrated 58% reduction in SSI NDA submission expected in Q1 2026 Unveiled a Long-Acting GLP-1 Receptor Agonists Delivery Platform Targeting the Obesity and Diabetes
Nayax Reports Second Quarter 2025 Results GlobeNewswire August 13, 2025 Revenue of $95.6 million, recurring revenue growth of 32% Gross margin improves to 48.3% Net income of $11.7 million with Adjusted EBITDA of $12.6 million(1) Total transaction value up 34%, Customer base increases 24% Company reaffirms full year 2025 guidance HERZLIYA, Israel, Aug. 13, 2025
LIXTE Biotechnology Holdings Updates Corporate Treasury Policy to Include Cryptocurrency GlobeNewswire August 13, 2025 PASADENA, Calif., Aug. 13, 2025 (GLOBE NEWSWIRE) — LIXTE Biotechnology Holdings, Inc. (“LIXTE” or the “Company”) (Nasdaq: LIXT and LIXTW), a clinical stage pharmaceutical company, today announced that its Board of Directors has approved a strategic capital allocation initiative to acquire
Nasus Pharma Announces Pricing of $10 Million Initial Public Offering GlobeNewswire August 13, 2025 TEL AVIV, Israel, Aug. 13, 2025 (GLOBE NEWSWIRE) — Nasus Pharma Ltd. (NYSE: NSRX) (“Nasus Pharma” or the “Company”), a clinical-stage pharmaceutical company focused on the development of innovative intranasal products to treat emergency medical conditions, today announced the pricing of
NEW YORK, NY / ACCESS Newswire / August 13, 2025 / If you suffered a loss on your Altimmune, Inc. (NASDAQ:ALT) investment and want to learn about a potential recovery under the federal securities laws, follow the link below for more information: https://zlk.com/pslra-1/altimmune-inc-lawsuit-submission-form-2?prid=161195&wire=1&utm_campaign=10 or contact Joseph E. Levi, Esq. via email at jlevi@levikorsinsky.com or call
NEW YORK, NY / ACCESS Newswire / August 13, 2025 / If you suffered a loss on your Sable Offshore Corp. (NYSE:SOC) investment and want to learn about a potential recovery under the federal securities laws, follow the link below for more information: https://zlk.com/pslra-1/sable-offshore-corp-lawsuit-submission-form?prid=161194&wire=1&utm_campaign=4 or contact Joseph E. Levi, Esq. via email at jlevi@levikorsinsky.com or
NEW YORK, NY / ACCESS Newswire / August 13, 2025 / If you suffered a loss on your Novo Nordisk A/S (NYSE:NVO) investment and want to learn about a potential recovery under the federal securities laws, follow the link below for more information: https://zlk.com/pslra-1/novo-nordisk-a-s-lawsuit-submission-form-3?prid=161201&wire=1&utm_campaign=26 or contact Joseph E. Levi, Esq. via email at jlevi@levikorsinsky.com or